Leukemie - úvodem

Karel Indrák

Onkologie. 2008:2(3):144  

USE OF ALL-TRANS-RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA - MORE THAN SUCCESSFUL MODEL OF TARGETED TREATMENT IN HEMATOONCOLOGY

Tomáš Szotkowski, Edgar Faber, Jan Starý, Jaromír Hubáček, Romana Szotkowská, PhDr. Milena Holzerová, doc. PhDr. Marie Jarošová CSc, Karel Indrák

Onkologie. 2008:2(3):145-149  

Acute promyelocytic leukemia (APL) belongs to less frequent subtypes of acute myeloid leukemia. However, APL is a very important entity being one of the first malignant diseases treated by targeted therapy and the only one acute myeloid leukemia with a really favorable prognosis. All-trans-retinoic acid (ATRA) caused a real revolution in APL treatment 20 years ago. A vast majority of patients died from intracranial bleeding shortly after diagnosis before the inclusion of ATRA in front-line treatment. Nowadays, it is possible to achieve a long-term remission and perhaps to completely cure 70–80 % of patients.

CHRONIC MYELOID LEUKEMIA - FROM MOLECULAR PATHOGENESIS TO TARGETED THERAPY

Peter Rohoň, Daniela Žáčková

Onkologie. 2008:2(3):150-155  

Chronic myeloid leukemia (CML) is the myeloproliferative disorder characterized by the presence of Philadelphia chromosome (Ph) and/or BCR/ABL fusion gene. Imatinib mesylate (IM, Glivec®) was developed as the first molecularly targeted therapy that specifically inhibits the Bcr/Abl tyrosine kinase (TK). IM becomes first-line treatment for patients with newly diagnosed CML in chronic phase. Nevertheless, resistance to the drug has been frequently reported and it presents dominant problem in 20–30 % of CML patients after 5 years of treatment. Point mutations within Abl kinase domain are regarded as the major cause of resistance. In some...

CHRONIC LYMPHOCYTIC LEUKEMIA

Tomáš Kozák

Onkologie. 2008:2(3):156-162  

Chronic lymphocytic leukemia (CLL) is a clonal disease of B lymphocyte with extremly variable course and prognosis. From biological point of view it is a heterogenneic disorder resulting from the imbalance between proliferation activity of the clone and apoptosis. Clinical staging and indication for the therapy initiation is stable for years, however, prognostic factors assessment is useful during the management and follow up of patients with CLL. New therapeutic approaches were developed during past years. A combination of chemotherapy and immunotherapy represents the most used strategy in the treatment of CLL having influence on major variables in...

HAIRY CELL LEUKEMIA

Luděk Raida, Karel Indrák, Pavel Žák

Onkologie. 2008:2(3):163-166  

Fifty years ago, hairy cell leukemia, relatively rare disease, was identified as an independent unit among the hematological malignancies. Over this period its treatment developed and the lymphoproliferative disease with fatal prognosis has become relatively benign one with longer survival of patients and normalized quality of their life. Hematological stabilization in splenectomised patients and the high therapeutic efficacy of lymphocytotoxic purine analogues, particularly cladribine, make the hairy cell leukemia to be a specific malignancy. It seems to be a feasible model for the investigation of the role of immunocompetent cells in the pathogenesis...

ACUTE LYMPHOBLASTIC LEUKAEMIA IN ADOLESCENTS AND YOUNG ADULTS - AN IDENTICAL BIOLOGICAL CATEGORY?

Vladimír Mihál

Onkologie. 2008:2(3):167-172  

The authors of this paper try to find an answer to the question why the treatment outcomes of acute lymphoblastic leukaemia (ALL) in adolescents and young adults are significantly worse when compared to those of children with ALL. They briefly present the major factors which determine treatment outcomes in age subgroups (age, immunophenotype, genetics, early response to treatment). The authors emphasise the need for international collaboration of paediatric and adult oncologists which should result in a unification of treatment protocols for adolescents and young adult patients with ALL based on their specific biology of disease.

CANCER ANOREXIA/CACHEXIA SYNDROME

Miroslav Tomíška

Onkologie. 2008:2(3):174-178  

Cancer cachexia is a syndrome of progressive weight loss which causes significant morbidity and mortality in cancer patients. Metabolic derangements conditioned by proinflammatory cytokines, ultimately leading to muscle and fat depletion, are frequently operating early after tumor onset so cancer cachexia has to be viewed as an early phenomenon. The presence of acute phase response accounts for limited effectiveness of nutritional therapy alone especially in advanced malnutrition. However, cancer cachexia in early stages is at least partially preventable. The easiest way of nutrition support is an early and systematic use of high-protein oral nutritional...

Léčebné postupy u pokročilých testikulárních germinálních nádorů

Jitka Abrahámová

Onkologie. 2008:2(3):179-185  

Therapy of Invasive Fungal Infection in Immunosuppressed Patients

Petr Sedláček

Onkologie. 2008:2(3):186-190  

Invasive fungal infection (IFI) remains to be a serious complication in patients with significant primary or secondary immunodeficiency. High–dose chemotherapy and/or therapy with potent immunosuppressants, allogeneic stem cell transplantation with increasing proportion of alternative donors are responsible for increasing number of patients suffering such life–threatening complication. Despite infections caused by yeasts in general population predominate, in heavily immunosuppressed patients we observe increase of invasive mold infections. One of important factors negatively influencing the efficiency of therapy is difficult diagnostics....

SRDEČNÍ TRANSPLANTACE U PACIENTKY S MALIGNÍM TUMOREM SRDCE

Helena Bedáňová, Jan Černý, Erik Petrikovits, Pavel Studeník, Jiří Ondrášek, Petr Němec, Alžběta Sirotková, Vladimír Spurný

Onkologie. 2008:2(3):193-195  

Tamoxifen a QT interval

Ladislav Slováček, Peter Priester, Miroslav Hodek, Jiří Petera, Stanislav Filip

Onkologie. 2008:2(3):196-197  

Předmět povinné mlčenlivosti zdravotnických pracovníků

Pavel Uherek

Onkologie. 2008:2(3):203-205  

Karlštejn 2008, česká uroonkologie a světový golf

Michaela Matoušková, Miroslav Hanuš

Onkologie. 2008:2(3):197  

XXII. olomoucké hematologické dny s mezinárodní účastí

Vít Procházka

Onkologie. 2008:2(3):198  

10th International Conference on Malignant Lymphoma, červen 2008, Lugano, Švýcarsko

Lenka Šmardová, Jozef Michalka, Martina Tošková

Onkologie. 2008:2(3):200  

Autodidaktický test č. 3/2008

Onkologie. 2008:2(3):191